Cardio Round-up: FOURIER Analysis, Alcohol AFib Risk; and More

In a landmark analysis of the FOURIER trial, the addition of the PCSK9 inhibitor evolocumab to moderate to intense statin therapy was associated with a reduced risk for complex coronary disease that would require complex revascularization. The greatest reductions over time were observed in the most complex of cases, prompting researchers to note that “aggressive LDL-C lowering may have beneficial effects on coronary atherosclerosis burden, anatomic complexity, and need for coronary revascularization.”

DocWire News also recently caught up with cardiologist Dr. Marc Bonaca, of the University of Colorado and a primary investigator of the VOYAGER-PAD study, to talk about recent exciting developments in atherosclerotic disease treatment, as well as the impact of COVID-19 on patients with atherosclerotic disease.

New research also has suggested that COVID-19 has impacted the number of heart failure referrals. A new study in the UK showed that during the eight weeks that followed the first reported death from COVID-19, there was a significant decrease in referrals for patients with acute heart failure (and a corresponding increase in mortality).

And for those who want a drink, note well this new research (echoing some previous research) suggesting that the consumption of alcohol, even at small amounts, is linked with an increased risk for atrial fibrillation.

In Case You Missed It

Study Finds Sodium Nitrite Does Not Improve Survival in Out-of-Hospital Cardiac Arrest

Ischemic Heart, Hypertensive Disease Deaths Up During COVID-19